Slingshot members are tracking this event:

Topline Results Released From Gilead's (GILD) Phase 2 ATLAS Study of cilofexor 30 mg, firsocostat 20 mg and selonsertib 18 mg in Patients With Bridging Fibrosis and Compensated Cirrhosis Due to NASH

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Study Primary Endpoint Was Not Met; Improvement in Multiple Measures of Fibrosis and Liver Injury Was Observed with Investigational Firsocostat and Cilofexor
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 16, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Atlas, Fibrosis, Bridging Fibrosis, Compensated Cirrhosis, Nash, Cilofexor, Firsocostat, Selonsertib